# Dalteparin in Preventing Blood Clots in Patients With Lung Cancer

> **NCT00519805** · PHASE3 · UNKNOWN · sponsor: **Velindre NHS Trust** · enrollment: 2200 (estimated)

## Conditions studied

- Lung Cancer
- Thromboembolism

## Interventions

- **DRUG:** dalteparin
- **PROCEDURE:** quality-of-life assessment

## Key facts

- **NCT ID:** NCT00519805
- **Lead sponsor:** Velindre NHS Trust
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2007-08
- **Primary completion:** 2012-08
- **Final completion:** —
- **Target enrollment:** 2200 (ESTIMATED)
- **Last updated:** 2011-08-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00519805

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00519805, "Dalteparin in Preventing Blood Clots in Patients With Lung Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00519805. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*